BMS Gets First Immunotherapy Approval In Neoadjuvant Lung Cancer, Quickly
Executive Summary
Opdivo gets approved by the US FDA for neoadjuvant non-small cell lung cancer, an important new early-stage indication for the anti-PD-1 agent that cleared the agency in roughly two months.
You may also be interested in...
AstraZeneca’s Imfinzi Scores Neoadjuvant/Adjuvant NSCLC Two-fer At AACR
The PD-L1 inhibitor showed efficacy in the neoadjuvant/adjuvant setting, where Merck is developing Keytruda as well. BMS’s Opdivo was the first to win approval in neoadjuvant NSCLC.
Can’t Win Them All: Two Merck Oncology Trials Fail
The company stopped a study of Lynparza in colorectal cancer for futility and announced a study of Keytruda/chemoradiation in head-and-neck cancer didn’t meet its primary endpoint.
AstraZeneca Looks To Muscle In On BMS-Dominated Neoadjuvant NSCLC Setting
Without disclosing data, the company reported positive pathological complete response data from the AEGEAN study of its PD-L1 inhibitor Imfinzi in neoadjuvant NSCLC, where BMS’s Opdivo won approval in March.